Fosun Forms JV with BioNTech to Manufacture COVID-19 Vaccine
December 30, 2020 at 06:27 AM EST
Shanghai Fosun Pharma will form a JV with its German partner BioNTech to manufacture COVID-19 vaccine in China. In March, Fosun acquired China rights to BioNTech's mRNA vaccine in a $135 million deal that included a $50 million Fosun investment in BioNTech. Under the agreement, Fosun agreed to purchase 100 million doses of the vaccine for China use. Now, the JV will follow that up by initially purchasing bulk ingredients from BioNTech to fill and finish, and then making vaccines itself in a facility with a 200 million dose capacity. More details.... Stock Symbols: (SHA: 600196; HK: 02196) Share this with colleagues: // //